nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—CYP2D6—Fingolimod—multiple sclerosis	0.113	0.184	CbGbCtD
Efavirenz—CYP3A4—Fingolimod—multiple sclerosis	0.0718	0.117	CbGbCtD
Efavirenz—CYP2C19—Prednisone—multiple sclerosis	0.058	0.0945	CbGbCtD
Efavirenz—CYP2B6—Dexamethasone—multiple sclerosis	0.0569	0.0928	CbGbCtD
Efavirenz—CYP3A4—Methylprednisolone—multiple sclerosis	0.0462	0.0754	CbGbCtD
Efavirenz—CYP2C19—Dexamethasone—multiple sclerosis	0.0362	0.059	CbGbCtD
Efavirenz—CYP3A4—Triamcinolone—multiple sclerosis	0.0351	0.0571	CbGbCtD
Efavirenz—CYP3A4—Mitoxantrone—multiple sclerosis	0.0337	0.055	CbGbCtD
Efavirenz—CYP2C9—Dexamethasone—multiple sclerosis	0.0301	0.049	CbGbCtD
Efavirenz—CYP3A4—Betamethasone—multiple sclerosis	0.0301	0.049	CbGbCtD
Efavirenz—CYP3A4—Prednisolone—multiple sclerosis	0.0297	0.0484	CbGbCtD
Efavirenz—CYP3A4—Prednisone—multiple sclerosis	0.028	0.0457	CbGbCtD
Efavirenz—CYP2D6—Dexamethasone—multiple sclerosis	0.0275	0.0448	CbGbCtD
Efavirenz—CYP3A4—Dexamethasone—multiple sclerosis	0.0175	0.0285	CbGbCtD
Efavirenz—Malaise—Betamethasone—multiple sclerosis	0.000239	0.000624	CcSEcCtD
Efavirenz—Malaise—Dexamethasone—multiple sclerosis	0.000239	0.000624	CcSEcCtD
Efavirenz—Vertigo—Dexamethasone—multiple sclerosis	0.000239	0.000622	CcSEcCtD
Efavirenz—Vertigo—Betamethasone—multiple sclerosis	0.000239	0.000622	CcSEcCtD
Efavirenz—Syncope—Dexamethasone—multiple sclerosis	0.000238	0.000621	CcSEcCtD
Efavirenz—Syncope—Betamethasone—multiple sclerosis	0.000238	0.000621	CcSEcCtD
Efavirenz—Arrhythmia—Prednisone—multiple sclerosis	0.000237	0.000619	CcSEcCtD
Efavirenz—Sweating—Methotrexate—multiple sclerosis	0.000237	0.000618	CcSEcCtD
Efavirenz—Haematuria—Methotrexate—multiple sclerosis	0.000236	0.000615	CcSEcCtD
Efavirenz—Shock—Triamcinolone—multiple sclerosis	0.000235	0.000613	CcSEcCtD
Efavirenz—Insomnia—Prednisolone—multiple sclerosis	0.000235	0.000613	CcSEcCtD
Efavirenz—Alopecia—Prednisone—multiple sclerosis	0.000235	0.000612	CcSEcCtD
Efavirenz—Shock—Methylprednisolone—multiple sclerosis	0.000234	0.000611	CcSEcCtD
Efavirenz—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000234	0.00061	CcSEcCtD
Efavirenz—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000234	0.000609	CcSEcCtD
Efavirenz—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000233	0.000609	CcSEcCtD
Efavirenz—Loss of consciousness—Betamethasone—multiple sclerosis	0.000233	0.000609	CcSEcCtD
Efavirenz—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000233	0.000608	CcSEcCtD
Efavirenz—Paraesthesia—Prednisolone—multiple sclerosis	0.000233	0.000608	CcSEcCtD
Efavirenz—Tachycardia—Triamcinolone—multiple sclerosis	0.000233	0.000608	CcSEcCtD
Efavirenz—Nausea—Azathioprine—multiple sclerosis	0.000233	0.000607	CcSEcCtD
Efavirenz—Tachycardia—Methylprednisolone—multiple sclerosis	0.000233	0.000606	CcSEcCtD
Efavirenz—Skin disorder—Methylprednisolone—multiple sclerosis	0.000231	0.000604	CcSEcCtD
Efavirenz—Erythema—Prednisone—multiple sclerosis	0.000231	0.000603	CcSEcCtD
Efavirenz—Malnutrition—Prednisone—multiple sclerosis	0.000231	0.000603	CcSEcCtD
Efavirenz—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000231	0.000602	CcSEcCtD
Efavirenz—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00023	0.000601	CcSEcCtD
Efavirenz—Convulsion—Betamethasone—multiple sclerosis	0.00023	0.0006	CcSEcCtD
Efavirenz—Convulsion—Dexamethasone—multiple sclerosis	0.00023	0.0006	CcSEcCtD
Efavirenz—Hypertension—Dexamethasone—multiple sclerosis	0.000229	0.000598	CcSEcCtD
Efavirenz—Hypertension—Betamethasone—multiple sclerosis	0.000229	0.000598	CcSEcCtD
Efavirenz—Asthenia—Mitoxantrone—multiple sclerosis	0.000227	0.000592	CcSEcCtD
Efavirenz—Myalgia—Dexamethasone—multiple sclerosis	0.000226	0.000589	CcSEcCtD
Efavirenz—Myalgia—Betamethasone—multiple sclerosis	0.000226	0.000589	CcSEcCtD
Efavirenz—Anxiety—Dexamethasone—multiple sclerosis	0.000225	0.000587	CcSEcCtD
Efavirenz—Anxiety—Betamethasone—multiple sclerosis	0.000225	0.000587	CcSEcCtD
Efavirenz—Discomfort—Dexamethasone—multiple sclerosis	0.000223	0.000582	CcSEcCtD
Efavirenz—Discomfort—Betamethasone—multiple sclerosis	0.000223	0.000582	CcSEcCtD
Efavirenz—Pain—Prednisolone—multiple sclerosis	0.000222	0.000579	CcSEcCtD
Efavirenz—Hepatitis—Methotrexate—multiple sclerosis	0.000222	0.000579	CcSEcCtD
Efavirenz—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000219	0.000572	CcSEcCtD
Efavirenz—Vision blurred—Prednisone—multiple sclerosis	0.000218	0.000568	CcSEcCtD
Efavirenz—Urethral disorder—Methotrexate—multiple sclerosis	0.000218	0.000567	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000218	0.000567	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000217	0.000566	CcSEcCtD
Efavirenz—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000217	0.000565	CcSEcCtD
Efavirenz—Insomnia—Triamcinolone—multiple sclerosis	0.000216	0.000563	CcSEcCtD
Efavirenz—Insomnia—Methylprednisolone—multiple sclerosis	0.000216	0.000562	CcSEcCtD
Efavirenz—Ill-defined disorder—Prednisone—multiple sclerosis	0.000215	0.000559	CcSEcCtD
Efavirenz—Paraesthesia—Triamcinolone—multiple sclerosis	0.000214	0.000559	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisolone—multiple sclerosis	0.000214	0.000558	CcSEcCtD
Efavirenz—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000214	0.000558	CcSEcCtD
Efavirenz—Visual impairment—Methotrexate—multiple sclerosis	0.000214	0.000558	CcSEcCtD
Efavirenz—Anaemia—Prednisone—multiple sclerosis	0.000214	0.000557	CcSEcCtD
Efavirenz—Shock—Dexamethasone—multiple sclerosis	0.000213	0.000556	CcSEcCtD
Efavirenz—Shock—Betamethasone—multiple sclerosis	0.000213	0.000556	CcSEcCtD
Efavirenz—Dyspnoea—Triamcinolone—multiple sclerosis	0.000213	0.000555	CcSEcCtD
Efavirenz—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000213	0.000554	CcSEcCtD
Efavirenz—Nervous system disorder—Betamethasone—multiple sclerosis	0.000213	0.000554	CcSEcCtD
Efavirenz—Agitation—Prednisone—multiple sclerosis	0.000212	0.000554	CcSEcCtD
Efavirenz—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000212	0.000553	CcSEcCtD
Efavirenz—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000212	0.000553	CcSEcCtD
Efavirenz—Tachycardia—Betamethasone—multiple sclerosis	0.000211	0.000552	CcSEcCtD
Efavirenz—Tachycardia—Dexamethasone—multiple sclerosis	0.000211	0.000552	CcSEcCtD
Efavirenz—Angioedema—Prednisone—multiple sclerosis	0.000211	0.000551	CcSEcCtD
Efavirenz—Dyspepsia—Triamcinolone—multiple sclerosis	0.00021	0.000548	CcSEcCtD
Efavirenz—Erythema multiforme—Methotrexate—multiple sclerosis	0.00021	0.000547	CcSEcCtD
Efavirenz—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00021	0.000547	CcSEcCtD
Efavirenz—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000209	0.000546	CcSEcCtD
Efavirenz—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000209	0.000546	CcSEcCtD
Efavirenz—Malaise—Prednisone—multiple sclerosis	0.000209	0.000544	CcSEcCtD
Efavirenz—Vertigo—Prednisone—multiple sclerosis	0.000208	0.000542	CcSEcCtD
Efavirenz—Eye disorder—Methotrexate—multiple sclerosis	0.000207	0.000541	CcSEcCtD
Efavirenz—Syncope—Prednisone—multiple sclerosis	0.000207	0.000541	CcSEcCtD
Efavirenz—Tinnitus—Methotrexate—multiple sclerosis	0.000207	0.00054	CcSEcCtD
Efavirenz—Anorexia—Betamethasone—multiple sclerosis	0.000207	0.000539	CcSEcCtD
Efavirenz—Anorexia—Dexamethasone—multiple sclerosis	0.000207	0.000539	CcSEcCtD
Efavirenz—Urticaria—Prednisolone—multiple sclerosis	0.000206	0.000538	CcSEcCtD
Efavirenz—Cardiac disorder—Methotrexate—multiple sclerosis	0.000206	0.000537	CcSEcCtD
Efavirenz—Fatigue—Triamcinolone—multiple sclerosis	0.000206	0.000537	CcSEcCtD
Efavirenz—Fatigue—Methylprednisolone—multiple sclerosis	0.000205	0.000536	CcSEcCtD
Efavirenz—Pain—Triamcinolone—multiple sclerosis	0.000204	0.000533	CcSEcCtD
Efavirenz—Loss of consciousness—Prednisone—multiple sclerosis	0.000203	0.00053	CcSEcCtD
Efavirenz—Angiopathy—Methotrexate—multiple sclerosis	0.000201	0.000525	CcSEcCtD
Efavirenz—Vomiting—Mitoxantrone—multiple sclerosis	0.000201	0.000525	CcSEcCtD
Efavirenz—Immune system disorder—Methotrexate—multiple sclerosis	0.000201	0.000523	CcSEcCtD
Efavirenz—Convulsion—Prednisone—multiple sclerosis	0.0002	0.000522	CcSEcCtD
Efavirenz—Mediastinal disorder—Methotrexate—multiple sclerosis	0.0002	0.000522	CcSEcCtD
Efavirenz—Hypertension—Prednisone—multiple sclerosis	0.0002	0.000521	CcSEcCtD
Efavirenz—Rash—Mitoxantrone—multiple sclerosis	0.0002	0.00052	CcSEcCtD
Efavirenz—Dermatitis—Mitoxantrone—multiple sclerosis	0.000199	0.00052	CcSEcCtD
Efavirenz—Headache—Mitoxantrone—multiple sclerosis	0.000198	0.000517	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000197	0.000515	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000197	0.000515	CcSEcCtD
Efavirenz—Arthralgia—Prednisone—multiple sclerosis	0.000197	0.000513	CcSEcCtD
Efavirenz—Myalgia—Prednisone—multiple sclerosis	0.000197	0.000513	CcSEcCtD
Efavirenz—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000197	0.000513	CcSEcCtD
Efavirenz—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000196	0.000512	CcSEcCtD
Efavirenz—Anxiety—Prednisone—multiple sclerosis	0.000196	0.000512	CcSEcCtD
Efavirenz—Alopecia—Methotrexate—multiple sclerosis	0.000196	0.000512	CcSEcCtD
Efavirenz—Insomnia—Dexamethasone—multiple sclerosis	0.000196	0.000511	CcSEcCtD
Efavirenz—Insomnia—Betamethasone—multiple sclerosis	0.000196	0.000511	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000195	0.00051	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000195	0.000508	CcSEcCtD
Efavirenz—Paraesthesia—Betamethasone—multiple sclerosis	0.000195	0.000507	CcSEcCtD
Efavirenz—Paraesthesia—Dexamethasone—multiple sclerosis	0.000195	0.000507	CcSEcCtD
Efavirenz—Discomfort—Prednisone—multiple sclerosis	0.000194	0.000507	CcSEcCtD
Efavirenz—Erythema—Methotrexate—multiple sclerosis	0.000193	0.000504	CcSEcCtD
Efavirenz—Malnutrition—Methotrexate—multiple sclerosis	0.000193	0.000504	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisolone—multiple sclerosis	0.000191	0.000499	CcSEcCtD
Efavirenz—Dyspepsia—Betamethasone—multiple sclerosis	0.000191	0.000497	CcSEcCtD
Efavirenz—Dyspepsia—Dexamethasone—multiple sclerosis	0.000191	0.000497	CcSEcCtD
Efavirenz—Urticaria—Triamcinolone—multiple sclerosis	0.00019	0.000495	CcSEcCtD
Efavirenz—Urticaria—Methylprednisolone—multiple sclerosis	0.000189	0.000494	CcSEcCtD
Efavirenz—Dysgeusia—Methotrexate—multiple sclerosis	0.000189	0.000493	CcSEcCtD
Efavirenz—Body temperature increased—Triamcinolone—multiple sclerosis	0.000189	0.000492	CcSEcCtD
Efavirenz—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000188	0.000491	CcSEcCtD
Efavirenz—Decreased appetite—Betamethasone—multiple sclerosis	0.000188	0.000491	CcSEcCtD
Efavirenz—Decreased appetite—Dexamethasone—multiple sclerosis	0.000188	0.000491	CcSEcCtD
Efavirenz—Nausea—Mitoxantrone—multiple sclerosis	0.000188	0.00049	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000187	0.000488	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000187	0.000488	CcSEcCtD
Efavirenz—Back pain—Methotrexate—multiple sclerosis	0.000187	0.000487	CcSEcCtD
Efavirenz—Fatigue—Betamethasone—multiple sclerosis	0.000187	0.000487	CcSEcCtD
Efavirenz—Fatigue—Dexamethasone—multiple sclerosis	0.000187	0.000487	CcSEcCtD
Efavirenz—Shock—Prednisone—multiple sclerosis	0.000186	0.000484	CcSEcCtD
Efavirenz—Pain—Betamethasone—multiple sclerosis	0.000185	0.000483	CcSEcCtD
Efavirenz—Pain—Dexamethasone—multiple sclerosis	0.000185	0.000483	CcSEcCtD
Efavirenz—Nervous system disorder—Prednisone—multiple sclerosis	0.000185	0.000483	CcSEcCtD
Efavirenz—Tachycardia—Prednisone—multiple sclerosis	0.000184	0.00048	CcSEcCtD
Efavirenz—Skin disorder—Prednisone—multiple sclerosis	0.000183	0.000478	CcSEcCtD
Efavirenz—Hyperhidrosis—Prednisone—multiple sclerosis	0.000182	0.000476	CcSEcCtD
Efavirenz—Vision blurred—Methotrexate—multiple sclerosis	0.000182	0.000475	CcSEcCtD
Efavirenz—Anorexia—Prednisone—multiple sclerosis	0.00018	0.000469	CcSEcCtD
Efavirenz—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000179	0.000468	CcSEcCtD
Efavirenz—Anaemia—Methotrexate—multiple sclerosis	0.000179	0.000466	CcSEcCtD
Efavirenz—Feeling abnormal—Betamethasone—multiple sclerosis	0.000179	0.000466	CcSEcCtD
Efavirenz—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000179	0.000466	CcSEcCtD
Efavirenz—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000177	0.000462	CcSEcCtD
Efavirenz—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000177	0.000462	CcSEcCtD
Efavirenz—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000176	0.000459	CcSEcCtD
Efavirenz—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000176	0.000458	CcSEcCtD
Efavirenz—Malaise—Methotrexate—multiple sclerosis	0.000174	0.000454	CcSEcCtD
Efavirenz—Vertigo—Methotrexate—multiple sclerosis	0.000174	0.000453	CcSEcCtD
Efavirenz—Urticaria—Betamethasone—multiple sclerosis	0.000172	0.000449	CcSEcCtD
Efavirenz—Urticaria—Dexamethasone—multiple sclerosis	0.000172	0.000449	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000172	0.000448	CcSEcCtD
Efavirenz—Dizziness—Prednisolone—multiple sclerosis	0.000172	0.000448	CcSEcCtD
Efavirenz—Asthenia—Triamcinolone—multiple sclerosis	0.000171	0.000447	CcSEcCtD
Efavirenz—Body temperature increased—Dexamethasone—multiple sclerosis	0.000171	0.000447	CcSEcCtD
Efavirenz—Abdominal pain—Betamethasone—multiple sclerosis	0.000171	0.000447	CcSEcCtD
Efavirenz—Abdominal pain—Dexamethasone—multiple sclerosis	0.000171	0.000447	CcSEcCtD
Efavirenz—Body temperature increased—Betamethasone—multiple sclerosis	0.000171	0.000447	CcSEcCtD
Efavirenz—Asthenia—Methylprednisolone—multiple sclerosis	0.000171	0.000446	CcSEcCtD
Efavirenz—Insomnia—Prednisone—multiple sclerosis	0.000171	0.000445	CcSEcCtD
Efavirenz—Paraesthesia—Prednisone—multiple sclerosis	0.000169	0.000442	CcSEcCtD
Efavirenz—Pruritus—Triamcinolone—multiple sclerosis	0.000169	0.000441	CcSEcCtD
Efavirenz—Cough—Methotrexate—multiple sclerosis	0.000169	0.00044	CcSEcCtD
Efavirenz—Pruritus—Methylprednisolone—multiple sclerosis	0.000169	0.00044	CcSEcCtD
Efavirenz—Convulsion—Methotrexate—multiple sclerosis	0.000167	0.000437	CcSEcCtD
Efavirenz—Dyspepsia—Prednisone—multiple sclerosis	0.000166	0.000433	CcSEcCtD
Efavirenz—Myalgia—Methotrexate—multiple sclerosis	0.000165	0.000429	CcSEcCtD
Efavirenz—Arthralgia—Methotrexate—multiple sclerosis	0.000165	0.000429	CcSEcCtD
Efavirenz—Chest pain—Methotrexate—multiple sclerosis	0.000165	0.000429	CcSEcCtD
Efavirenz—Decreased appetite—Prednisone—multiple sclerosis	0.000164	0.000428	CcSEcCtD
Efavirenz—Rash—Prednisolone—multiple sclerosis	0.000164	0.000427	CcSEcCtD
Efavirenz—Dermatitis—Prednisolone—multiple sclerosis	0.000164	0.000427	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000163	0.000426	CcSEcCtD
Efavirenz—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000163	0.000425	CcSEcCtD
Efavirenz—Fatigue—Prednisone—multiple sclerosis	0.000163	0.000424	CcSEcCtD
Efavirenz—Headache—Prednisolone—multiple sclerosis	0.000163	0.000424	CcSEcCtD
Efavirenz—Discomfort—Methotrexate—multiple sclerosis	0.000163	0.000424	CcSEcCtD
Efavirenz—Constipation—Prednisone—multiple sclerosis	0.000161	0.000421	CcSEcCtD
Efavirenz—Confusional state—Methotrexate—multiple sclerosis	0.000159	0.000415	CcSEcCtD
Efavirenz—Dizziness—Triamcinolone—multiple sclerosis	0.000158	0.000412	CcSEcCtD
Efavirenz—Dizziness—Methylprednisolone—multiple sclerosis	0.000158	0.000411	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisone—multiple sclerosis	0.000156	0.000406	CcSEcCtD
Efavirenz—Asthenia—Dexamethasone—multiple sclerosis	0.000155	0.000405	CcSEcCtD
Efavirenz—Asthenia—Betamethasone—multiple sclerosis	0.000155	0.000405	CcSEcCtD
Efavirenz—Nervous system disorder—Methotrexate—multiple sclerosis	0.000155	0.000403	CcSEcCtD
Efavirenz—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000154	0.000403	CcSEcCtD
Efavirenz—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000154	0.000402	CcSEcCtD
Efavirenz—Nausea—Prednisolone—multiple sclerosis	0.000154	0.000402	CcSEcCtD
Efavirenz—Pruritus—Dexamethasone—multiple sclerosis	0.000153	0.0004	CcSEcCtD
Efavirenz—Pruritus—Betamethasone—multiple sclerosis	0.000153	0.0004	CcSEcCtD
Efavirenz—Skin disorder—Methotrexate—multiple sclerosis	0.000153	0.000399	CcSEcCtD
Efavirenz—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000152	0.000398	CcSEcCtD
Efavirenz—Vomiting—Triamcinolone—multiple sclerosis	0.000152	0.000396	CcSEcCtD
Efavirenz—Vomiting—Methylprednisolone—multiple sclerosis	0.000152	0.000395	CcSEcCtD
Efavirenz—Rash—Triamcinolone—multiple sclerosis	0.000151	0.000393	CcSEcCtD
Efavirenz—Dermatitis—Triamcinolone—multiple sclerosis	0.00015	0.000392	CcSEcCtD
Efavirenz—Anorexia—Methotrexate—multiple sclerosis	0.00015	0.000392	CcSEcCtD
Efavirenz—Rash—Methylprednisolone—multiple sclerosis	0.00015	0.000392	CcSEcCtD
Efavirenz—Dermatitis—Methylprednisolone—multiple sclerosis	0.00015	0.000391	CcSEcCtD
Efavirenz—Urticaria—Prednisone—multiple sclerosis	0.00015	0.000391	CcSEcCtD
Efavirenz—Headache—Triamcinolone—multiple sclerosis	0.00015	0.00039	CcSEcCtD
Efavirenz—Headache—Methylprednisolone—multiple sclerosis	0.000149	0.000389	CcSEcCtD
Efavirenz—Body temperature increased—Prednisone—multiple sclerosis	0.000149	0.000389	CcSEcCtD
Efavirenz—Abdominal pain—Prednisone—multiple sclerosis	0.000149	0.000389	CcSEcCtD
Efavirenz—Diarrhoea—Dexamethasone—multiple sclerosis	0.000148	0.000387	CcSEcCtD
Efavirenz—Diarrhoea—Betamethasone—multiple sclerosis	0.000148	0.000387	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000144	0.000375	CcSEcCtD
Efavirenz—Dizziness—Dexamethasone—multiple sclerosis	0.000143	0.000374	CcSEcCtD
Efavirenz—Dizziness—Betamethasone—multiple sclerosis	0.000143	0.000374	CcSEcCtD
Efavirenz—Insomnia—Methotrexate—multiple sclerosis	0.000143	0.000372	CcSEcCtD
Efavirenz—Nausea—Triamcinolone—multiple sclerosis	0.000142	0.00037	CcSEcCtD
Efavirenz—Paraesthesia—Methotrexate—multiple sclerosis	0.000142	0.000369	CcSEcCtD
Efavirenz—Nausea—Methylprednisolone—multiple sclerosis	0.000142	0.000369	CcSEcCtD
Efavirenz—Dyspnoea—Methotrexate—multiple sclerosis	0.000141	0.000367	CcSEcCtD
Efavirenz—Somnolence—Methotrexate—multiple sclerosis	0.00014	0.000366	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisone—multiple sclerosis	0.000139	0.000363	CcSEcCtD
Efavirenz—Dyspepsia—Methotrexate—multiple sclerosis	0.000139	0.000362	CcSEcCtD
Efavirenz—Vomiting—Betamethasone—multiple sclerosis	0.000138	0.000359	CcSEcCtD
Efavirenz—Vomiting—Dexamethasone—multiple sclerosis	0.000138	0.000359	CcSEcCtD
Efavirenz—Decreased appetite—Methotrexate—multiple sclerosis	0.000137	0.000358	CcSEcCtD
Efavirenz—Rash—Betamethasone—multiple sclerosis	0.000137	0.000356	CcSEcCtD
Efavirenz—Rash—Dexamethasone—multiple sclerosis	0.000137	0.000356	CcSEcCtD
Efavirenz—Dermatitis—Dexamethasone—multiple sclerosis	0.000137	0.000356	CcSEcCtD
Efavirenz—Dermatitis—Betamethasone—multiple sclerosis	0.000137	0.000356	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000136	0.000355	CcSEcCtD
Efavirenz—Fatigue—Methotrexate—multiple sclerosis	0.000136	0.000355	CcSEcCtD
Efavirenz—Headache—Dexamethasone—multiple sclerosis	0.000136	0.000354	CcSEcCtD
Efavirenz—Headache—Betamethasone—multiple sclerosis	0.000136	0.000354	CcSEcCtD
Efavirenz—Asthenia—Prednisone—multiple sclerosis	0.000135	0.000353	CcSEcCtD
Efavirenz—Pain—Methotrexate—multiple sclerosis	0.000135	0.000352	CcSEcCtD
Efavirenz—Pruritus—Prednisone—multiple sclerosis	0.000134	0.000348	CcSEcCtD
Efavirenz—Feeling abnormal—Methotrexate—multiple sclerosis	0.00013	0.000339	CcSEcCtD
Efavirenz—Diarrhoea—Prednisone—multiple sclerosis	0.000129	0.000337	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000129	0.000336	CcSEcCtD
Efavirenz—Nausea—Dexamethasone—multiple sclerosis	0.000129	0.000336	CcSEcCtD
Efavirenz—Nausea—Betamethasone—multiple sclerosis	0.000129	0.000336	CcSEcCtD
Efavirenz—Urticaria—Methotrexate—multiple sclerosis	0.000125	0.000327	CcSEcCtD
Efavirenz—Dizziness—Prednisone—multiple sclerosis	0.000125	0.000325	CcSEcCtD
Efavirenz—Body temperature increased—Methotrexate—multiple sclerosis	0.000125	0.000325	CcSEcCtD
Efavirenz—Abdominal pain—Methotrexate—multiple sclerosis	0.000125	0.000325	CcSEcCtD
Efavirenz—Vomiting—Prednisone—multiple sclerosis	0.00012	0.000313	CcSEcCtD
Efavirenz—Rash—Prednisone—multiple sclerosis	0.000119	0.00031	CcSEcCtD
Efavirenz—Dermatitis—Prednisone—multiple sclerosis	0.000119	0.00031	CcSEcCtD
Efavirenz—Headache—Prednisone—multiple sclerosis	0.000118	0.000308	CcSEcCtD
Efavirenz—Hypersensitivity—Methotrexate—multiple sclerosis	0.000116	0.000303	CcSEcCtD
Efavirenz—Asthenia—Methotrexate—multiple sclerosis	0.000113	0.000295	CcSEcCtD
Efavirenz—Nausea—Prednisone—multiple sclerosis	0.000112	0.000292	CcSEcCtD
Efavirenz—Pruritus—Methotrexate—multiple sclerosis	0.000112	0.000291	CcSEcCtD
Efavirenz—Diarrhoea—Methotrexate—multiple sclerosis	0.000108	0.000281	CcSEcCtD
Efavirenz—Dizziness—Methotrexate—multiple sclerosis	0.000104	0.000272	CcSEcCtD
Efavirenz—Vomiting—Methotrexate—multiple sclerosis	0.0001	0.000261	CcSEcCtD
Efavirenz—Rash—Methotrexate—multiple sclerosis	9.94e-05	0.000259	CcSEcCtD
Efavirenz—Dermatitis—Methotrexate—multiple sclerosis	9.93e-05	0.000259	CcSEcCtD
Efavirenz—Headache—Methotrexate—multiple sclerosis	9.88e-05	0.000258	CcSEcCtD
Efavirenz—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	9.37e-05	0.0318	CbGpPWpGaD
Efavirenz—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	9.37e-05	0.0318	CbGpPWpGaD
Efavirenz—Nausea—Methotrexate—multiple sclerosis	9.37e-05	0.000244	CcSEcCtD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	6.46e-05	0.0219	CbGpPWpGaD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	6.46e-05	0.0219	CbGpPWpGaD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	5.95e-05	0.0202	CbGpPWpGaD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	5.95e-05	0.0202	CbGpPWpGaD
Efavirenz—CYP2B6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	5.87e-05	0.0199	CbGpPWpGaD
Efavirenz—CYP2B6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	5.87e-05	0.0199	CbGpPWpGaD
Efavirenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	5.52e-05	0.0187	CbGpPWpGaD
Efavirenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	5.52e-05	0.0187	CbGpPWpGaD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	4.82e-05	0.0163	CbGpPWpGaD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	4.82e-05	0.0163	CbGpPWpGaD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	4.5e-05	0.0152	CbGpPWpGaD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	4.5e-05	0.0152	CbGpPWpGaD
Efavirenz—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	4.44e-05	0.015	CbGpPWpGaD
Efavirenz—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	4.44e-05	0.015	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	4.26e-05	0.0144	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	4.26e-05	0.0144	CbGpPWpGaD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	4.14e-05	0.014	CbGpPWpGaD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	4.14e-05	0.014	CbGpPWpGaD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	4.1e-05	0.0139	CbGpPWpGaD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	4.1e-05	0.0139	CbGpPWpGaD
Efavirenz—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	4.08e-05	0.0138	CbGpPWpGaD
Efavirenz—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	4.08e-05	0.0138	CbGpPWpGaD
Efavirenz—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	4.05e-05	0.0137	CbGpPWpGaD
Efavirenz—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	4.05e-05	0.0137	CbGpPWpGaD
Efavirenz—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	3.77e-05	0.0128	CbGpPWpGaD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	3.65e-05	0.0124	CbGpPWpGaD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	3.65e-05	0.0124	CbGpPWpGaD
Efavirenz—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	3.5e-05	0.0119	CbGpPWpGaD
Efavirenz—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	3.5e-05	0.0119	CbGpPWpGaD
Efavirenz—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	3.46e-05	0.0117	CbGpPWpGaD
Efavirenz—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	3.46e-05	0.0117	CbGpPWpGaD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	3.35e-05	0.0114	CbGpPWpGaD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	3.35e-05	0.0114	CbGpPWpGaD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	3.32e-05	0.0113	CbGpPWpGaD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	3.32e-05	0.0113	CbGpPWpGaD
Efavirenz—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	3.07e-05	0.0104	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	3e-05	0.0102	CbGpPWpGaD
Efavirenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	2.84e-05	0.00962	CbGpPWpGaD
Efavirenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	2.84e-05	0.00962	CbGpPWpGaD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	2.7e-05	0.00916	CbGpPWpGaD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	2.7e-05	0.00916	CbGpPWpGaD
Efavirenz—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	2.67e-05	0.00904	CbGpPWpGaD
Efavirenz—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	2.67e-05	0.00904	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	2.56e-05	0.00868	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	2.56e-05	0.00868	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	2.53e-05	0.00856	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	2.53e-05	0.00856	CbGpPWpGaD
Efavirenz—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	2.43e-05	0.00822	CbGpPWpGaD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	2.19e-05	0.00743	CbGpPWpGaD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	2.19e-05	0.00743	CbGpPWpGaD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	2.11e-05	0.00716	CbGpPWpGaD
Efavirenz—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	2.11e-05	0.00714	CbGpPWpGaD
Efavirenz—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	1.94e-05	0.00656	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	1.94e-05	0.00656	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	1.94e-05	0.00656	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.91e-05	0.00647	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.91e-05	0.00647	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	1.89e-05	0.00639	CbGpPWpGaD
Efavirenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.81e-05	0.00612	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	1.78e-05	0.00603	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	1.78e-05	0.00603	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	1.77e-05	0.00598	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	1.77e-05	0.00598	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.76e-05	0.00595	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.76e-05	0.00595	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.74e-05	0.0059	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.74e-05	0.0059	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	1.67e-05	0.00565	CbGpPWpGaD
Efavirenz—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	1.64e-05	0.00556	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	1.51e-05	0.00511	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	1.51e-05	0.00511	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.49e-05	0.00504	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.49e-05	0.00504	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.39e-05	0.00472	CbGpPWpGaD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.34e-05	0.00454	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	1.16e-05	0.00395	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	1.16e-05	0.00395	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.15e-05	0.00389	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.15e-05	0.00389	CbGpPWpGaD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.09e-05	0.00368	CbGpPWpGaD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.01e-05	0.00343	CbGpPWpGaD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.3e-06	0.00315	CbGpPWpGaD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.22e-06	0.00313	CbGpPWpGaD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.2e-06	0.00278	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	8.11e-06	0.00275	CbGpPWpGaD
Efavirenz—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.88e-06	0.00267	CbGpPWpGaD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.54e-06	0.00256	CbGpPWpGaD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.48e-06	0.00253	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.44e-06	0.00252	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.44e-06	0.00252	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	7.23e-06	0.00245	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	7.21e-06	0.00244	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.78e-06	0.0023	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.78e-06	0.0023	CbGpPWpGaD
Efavirenz—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.39e-06	0.00216	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—SRM—multiple sclerosis	6.22e-06	0.00211	CbGpPWpGaD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.08e-06	0.00206	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.79e-06	0.00196	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.79e-06	0.00196	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—POMC—multiple sclerosis	5.76e-06	0.00195	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	5.64e-06	0.00191	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	5.62e-06	0.0019	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	5.51e-06	0.00187	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.25e-06	0.00178	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	5.25e-06	0.00178	CbGpPWpGaD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.93e-06	0.00167	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—SRM—multiple sclerosis	4.7e-06	0.00159	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	4.38e-06	0.00148	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	4.38e-06	0.00148	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—POMC—multiple sclerosis	4.36e-06	0.00148	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—SRM—multiple sclerosis	4.32e-06	0.00146	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—SRM—multiple sclerosis	4.29e-06	0.00145	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GPC5—multiple sclerosis	4.01e-06	0.00136	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—POMC—multiple sclerosis	4.01e-06	0.00136	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.97e-06	0.00135	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—SRM—multiple sclerosis	3.66e-06	0.00124	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—POMC—multiple sclerosis	3.39e-06	0.00115	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—RRM1—multiple sclerosis	3.32e-06	0.00113	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	3.31e-06	0.00112	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	3.31e-06	0.00112	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.24e-06	0.0011	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	3.05e-06	0.00103	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	3.05e-06	0.00103	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GPC5—multiple sclerosis	3.03e-06	0.00103	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	3.02e-06	0.00102	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	3.02e-06	0.00102	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.95e-06	0.001	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—SRM—multiple sclerosis	2.83e-06	0.000958	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.79e-06	0.000944	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.76e-06	0.000936	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.62e-06	0.000888	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.58e-06	0.000874	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.58e-06	0.000874	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.52e-06	0.000854	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.51e-06	0.00085	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GPC5—multiple sclerosis	2.36e-06	0.0008	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.31e-06	0.000782	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.29e-06	0.000775	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.99e-06	0.000675	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.99e-06	0.000675	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.96e-06	0.000663	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.95e-06	0.00066	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.91e-06	0.000646	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.82e-06	0.000617	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.78e-06	0.000602	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.67e-06	0.000567	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.53e-06	0.000517	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.52e-06	0.000517	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.52e-06	0.000514	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.51e-06	0.000511	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.44e-06	0.000488	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.39e-06	0.000471	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.33e-06	0.000449	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.31e-06	0.000445	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.3e-06	0.000442	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.19e-06	0.000403	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—APOE—multiple sclerosis	1.15e-06	0.000389	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.12e-06	0.000381	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—POMC—multiple sclerosis	9.86e-07	0.000334	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—ALB—multiple sclerosis	8.99e-07	0.000305	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—APOE—multiple sclerosis	8.67e-07	0.000294	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.67e-07	0.000294	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—APOE—multiple sclerosis	7.98e-07	0.00027	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—APOE—multiple sclerosis	7.91e-07	0.000268	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—POMC—multiple sclerosis	7.45e-07	0.000252	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—POMC—multiple sclerosis	6.85e-07	0.000232	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—POMC—multiple sclerosis	6.79e-07	0.00023	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—ALB—multiple sclerosis	6.79e-07	0.00023	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—APOE—multiple sclerosis	6.76e-07	0.000229	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—ALB—multiple sclerosis	6.25e-07	0.000212	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—ALB—multiple sclerosis	6.19e-07	0.00021	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—POMC—multiple sclerosis	5.8e-07	0.000197	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—ALB—multiple sclerosis	5.29e-07	0.000179	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—APOE—multiple sclerosis	5.21e-07	0.000177	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—POMC—multiple sclerosis	4.48e-07	0.000152	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—ALB—multiple sclerosis	4.08e-07	0.000138	CbGpPWpGaD
